PROPHASE LABS, INC. (NASDAQ:PRPH) Files An 8-K Other EventsItem 8.01 Other Events.
On December 19, 2017, ProPhase Labs, Inc. (“ProPhase”) issued a press release announcing the preliminary results of its tender offer for ProPhase common stock, which expired at midnight, New York City time, on December 18, 2017. That press release is filed as Exhibit 99.1 hereto.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
| No. | Description |
| 99.1 | Press release announcing the preliminary results of the Tender Offer, dated December 19, 2017 |
ProPhase Labs, Inc. ExhibitEX-99.1 2 ex99-1.htm PRESS RELEASE PROPHASE LABS,…To view the full exhibit click here
About PROPHASE LABS, INC. (NASDAQ:PRPH)
ProPhase Labs, Inc. is a manufacturer, marketer and distributor of a range of homeopathic and health products. The Company is also engaged in the research and development of over-the-counter (OTC) drugs, natural base health products along with supplements, personal care and cosmeceutical products. It is engaged in manufacturing, distributing, marketing and sale of OTC cold remedy products to consumers through national chain, regional, specialty and local retail stores. It also manufactures, markets and distributes an organic cough drop and a Vitamin C supplement, Organix, and performs contract manufacturing services of cough drop, dietary supplements, and other OTC cold remedy products for third parties. Its product pipeline includes Cold-EEZE Cold Remedy QuickMelts and Cold-EEZE Cold Remedy Oral Spray. It also produces Legendz XL for sexual health, Triple Edge XL, which is a daily energy booster plus testosterone support, and Super ProstaFlow Plus for prostate and urinary health.
